这里是2019的九个核心时期，它将在前景几今年年底诠释整形科开刀手术服务器人市场中。

现如今医院医械服务行业最旺门的行业产品之一是产科工具人。通过Allied Market Research的份统计，该区域行业服务器在2014年为0.563000万澳元，平均到202历经四年将扩大至987.37亿澳元，預测时期的和好年扩大率为8.5%。去年 是整形科机人技术设备的暴涨增长期元年。MD+DI网页说说了去年 近视手术机人范围八个比较重要时间段。

达芬奇机械设备人：推动掉价攻略

洞察力急诊科自2000年荣获FDA许可主板上市到现在，一直以来都是做手术器机人股票市场的领军者。那么，争夺对友已会逐渐经常出现并增添。洞察力急诊科的管理层表达，随着时间推移争夺非常越猛烈，新產品的推出了，工司能够会实现“官降营销策略”来兑换更具的卖场，也也就是不断增加价值商务商谈和商务商谈用时的廷长。该品牌标识，这样的各式各样也可能引起销售收入振幅。但而言很多本来认定其报价过高的专科医院和医疗卫生中心局并不是，可能是个号话题。

CMR的几大获胜

加盟总部处在荷兰剑桥的CMR2021过得好啊。三月，公司的在C轮融资贷款中募集了2.43000万外币，在它的POS机人助手整形装备房地产业化。原来月，该工司做完了向地属印度尼西亚普纳的浩瀚银河护肤医院专家（Galaxy Care Hospital）卖出了其首台设配的买卖交易。CMR创立于5年之前，并在新闻媒介上三公开写出，愿意下年能取到FDA的同意。

Verb：新CEO就任

Verb是强生装修司的Ethicon相关部门和verly生物地理学装修司的合资经营商家。一项进行配合发现在verly（前谷哥生物地理学相关部门）与诸多医疗器械自动化装修司进行配合的时分。而是Verb在设立之初就异彩纷呈，但该装修司在2021一直以来比较安安静静。或许，近日6月，Verb继续称为今日头条要闻，当年它否认库尔特•阿扎尔巴津（Kurt Azarbarzin）将担任新ceo兼顶尖实施官。阿扎尔巴津曾是SurgiQuest的总裁强制审理官，到最近202007年被Conmed（康美）以2.65000万元收购站。Azarbarzin也是个厉害小人物，他接班了Verb前总裁强制审理官ScottHuennekens，交给于18年年年尾走出总部。

泰坦医疗器械（Titan Medical）：延期设计规划

泰坦医治品牌（Titan Medical）在体育运动丝机人内窥镜手术系统化上出现了个很大的问题，并在7月下旬公布取消其他有关的该公司成本费用和时候的预计，禁止開發。Titan Medical认为，风投达不到是引起延期的病因。既使，泰坦并是没有让它消停。该有限公司正去寻找募集2一千万美金的流动资金，以可以帮助这一活动的控制系统回到最初正路。

XACT：刷出FDA的市场销售获批

XACT机设备人单位的项目机设备人获得了FDA开卖核准。该平衡装置在CT牵引下经皮旋磨疗法时中而非选用。这儿加盟总部在印度的开刀手术POS机人品牌，头上的真令人诧异的其原因是，它是率先APP场景图片規划和导航导航，暂时无法手工进行作业的设备人模式，能够自动化进行不同检测设备在一类型临床护理APP和适合症中进行插入图和驻车制动进行作业。

强生：34亿欧元大量收购Auris

强生以34亿人艮币资金（相当于人艮币230万亿）对价收购公司的项目机械人公司的Auris，若果达到有一些计程表碑，还要有支出恰有23.10亿美金的超额或有资金。这也将将成为强生在收够整形科治疗电脑软件丝机人方法开放总部Orthotaxy每隔年 后重新在这一个的领域的出手。

Auris 是由整形科产品人先行者弗里德里克·莫尔（Frederic Moll）创于，他也也是世界各国技术丝机人龙头品牌Intuitive Surgical（直觉思维美容外科）的协力开创人其一，由是的达芬奇丝机人现占用了更大分额的市场中。Frederic Moll也在收购公司后假如强生。

Auris专注力于肺癌患者广州POS机人能力，其主导商品有的是款叫做Monarch的，可由内科主任医生确认一位驱动器做设定的广州POS机人，视情况加以引导一位帶有摄录机的仔细观察镜进人患者胃中，能用的 于疾病诊断性和方法性的支气管镜查，这样的查中主任医生需将测试仪器嵌入患者的鼻道或耳鼻喉。

美敦力：着力打造医治工具人欧陆风云5

5月24日，美敦力在投入人会议内容上发部了其新一带技术电脑人Hugo RAS。Hugo RAS施用功能模块化设计的解决处理计划书，重点村抑制微创手术机器设备人制造费和软件的思维障碍。

美敦力机构微创手术方法班级继续执行总监裁兼大总裁大人鲍勃·怀特说：“这实际上仅是颁布的一款楼盘新品设备人，我门是要建造设备人王国。”

去年同期1二月29日，美敦力就官宣了以17亿欧元（相当于百姓币120万元）品牌收购俄罗斯医治设施品牌Mazor Robotics下列不属于电脑人铺助工具微创项目软件平台，该品牌常见车辆为Mazor X制导平台和Renaissance电脑人铺助工具脊椎骨微创项目设施。

在高价回收完全后的1个月时间，美敦力在国外推新了Mazor X Stealth™机器手臂人辅助软件脊椎术机构。

Mazor X Stealth™ 电脑人pc软件系統将美敦力的Stealthpc软件与Mazor涉及的电脑人技术设备相连实际。完成交互设计式三维图規划和产品信息pc软件系統保证随时画面加以正确引导，可视化管理和导航栏，保证上班工艺流程可預测性和便捷性。它适用3D拍摄头，加以正确引导标识和机械化臂，以一直监控APP和医疗仪器对应于脊椎的位子，并按行动计划高精度位置定位这句话。

美敦力最新消息最季度、半年度（2020财年最最季度、半年度）营收屏幕上显示，在脊椎金融业务员的涨幅中，术丝机人现在对脊椎金融业务员涨幅达到推动功用。

在国产，监察政府部门同样的也在十分推进整形设备人的综合运用。《我们制造出2025》中，生物制品制药和高性价比指标整形健身器械是关键击破的中国有十大科技领域中的一种。《2017-2026年我们开刀手术设备人企业行业研究报告范文及未来十年市场趋势英文趋势英文报告范文》信息显示，在未来国内做手术工具人的制造行业投资规模将在2022年触达200亿。

而近视手术机子人我们对骨伤科值入物贸易市场的拉和动力非常的大，也成为所有骨伤科龙头老大的必争之岛。

译文方式：

One of the hottest markets in the medical device industry right now is surgical robotics. The space, valued at $56.3 million in 2017, is expected to grow to $98,737 million by 2024 with a CAGR of 8.5% during the forecast, according to a report from Allied Market Research. Growth is happening now and 2019 has been a breakout year for surgical robotics – from product unveilings to delays. MD+DI is counting down the Top 7 developments for Surgical Robotics in 2019.

The Art of Negotiation

For years Intuitive Surgical has been at the top of the surgical robotics market – having gained a nod from FDA for the da Vinci Robot in 2000. (Whew that’s a lot of lead time.) However, competitors are>increased price negotiations and elongated negotiation timelines as competition gets closer to launching new products. The company said these dynamics could also result in profit fluctuations. This could be a plus for some hospitals and healthcare centers that have had issues with the da Vinci’s pricing.

CMR’s Two Big Wins

Cambridge, UK-based CMR has had a good year. In September, the company raised $243 million (wow!) in a Series C round to commercialize its Versius robot-assisted surgery device. And then last month the company completed the sale of its first unit to the Galaxy Care Hospital in Pune, India. CMR was founded 5 years ago and has publicly stated in media outlets that it hopes to have a nod from FDA next year.

Verb’s New Leadership

Verb is a joint venture between Johnson & Johnson’s Ethicon Unit and Verily Life Sciences. The collaboration happened during the time when Verily (the former life sciences unit of Google) was partnering with numerous companies in the medtech and pharmaceutical space. While Verb made a big splash when it was first formed, the company has been fairly quiet in 2019. However, in June Verb>

When Titan Hit Pause

Titan Medical hit a huge roadblock with the Sport robotic surgical system and announced in mid-October that it was withdrawing all forecasts with respect to the cost and timing of the platform. The Toronto-based company said a lack of financing was the reason behind the delay. Titan isn’t letting this stop it, however. The company is seeking to raise $25 million in an offering that could help get the Sport’s system back>

XACT Brings Home OK from FDA

XACT Robotics secured a coveted FDA nod for its robotic system. The device was cleared for use during CT-guided percutaneous interventional procedures. The wow factor behind the Caesarea, Isreal-based company’s robot is that it is the first hands-free robotic system combining image-based planning and navigation with the insertion and steering of various instruments across an array of clinical applications and indications.

Johnson & Johnson’s Glow Up in Surgical Robotics

Johnson & Johnson pulled off>Frederic Moll, M.D., CEO and Founder of Auris Health, joined J&J. Moll is also known for cofounding Intuitive Surgical. With this acquisition and J&J’s Verb the company now has multiple shots>

Medtronic’s Done Dropping Hints

Medtronic teased us all year long with tidbits and hints about its upcoming soft-tissue surgical robotics system. After some delays in 2018 with scant details about the platform, the Dublin-based company opened up a bit in June with the announcement of a collaboration with Karl Storz. The firm said its upcoming robotic-assisted surgical platform would incorporate Karl Storz’s 3D vision systems and visualization components. To boot the two companies had been working style="box-sizing: border-box; background-color: transparent; color: rgb(0, 184, 214); text-decoration: none; font-weight: bold;">announced in August it would unveil the robot during an investor’s meeting in September. And that it did. After a lengthy demonstration, Medtronic said it anticipates submitting for CE mark in the Q1 of the company's fiscal year 2021 (Medtronic's fiscal year begins in April), and filing for a U.S. investigational device exemption to begin placing systems in U.S. hospitals, training surgeons, and gathering clinical data in the first half of its fiscal year 2021. If all goes as planned, the system could be available both in Europe and in the U.S. within the next 24 months.